Concepedia

Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer.

William D. Fox, Brian Higgins, Krista Maiese, Marija Drobnjak, Carlos Cordon‐Cardo, Howard I. Scher, David B. Agus

PubMed · 2002 · 104 citations · 35 references

Abstract

rhu alpha VEGF has cytostatic clinical activity in this androgen-independent prostate cancer xenograft model, and the addition of paclitaxel demonstrates increased clinical activity.

References

35

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

K. Jin Kim, Bing Li, Jane Winer et al. · Nature · 1993 · 3.6K citations

, , +11

Tumor Angiogenesis: A New Significant and Independent Prognostic Indicator in Early-Stage Breast Carcinoma

Noel Weidner, J Folkman, F. Pozza et al. · JNCI Journal of the National Cancer Institute · 1992 · 1.8K citations

Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma.

Noel Weidner, Peter R. Carroll, Jonathan Flax et al. · PubMed · 1993 · 1.6K citations · Full text

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.

Leonard G. Presta, H Chen, Shane J. O'Connor et al. · PubMed · 1997 · 1.6K citations

, , +15

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

Mark D. Pegram, A. Lipton, Daniel F. Hayes et al. · Journal of Clinical Oncology · 1998 · 1.1K citations